Actuate Therapeutics, Inc. Common stock (ACTU)vsargenx NV ADR (ARGX)
ACTU
Actuate Therapeutics, Inc. Common stock
$2.32
+4.98%
HEALTHCARE · Cap: $136.67M
ARGX
argenx NV ADR
$697.05
+2.89%
HEALTHCARE · Cap: $42.05B
Smart Verdict
WallStSmart Research — data-driven comparison
ARGX leads profitability with a 30.5% profit margin vs 0.0%. ARGX earns a higher WallStSmart Score of 63/100 (C+).
ACTU
Avoid22
out of 100
Grade: F
ARGX
Buy63
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for ACTU.
Margin of Safety
-526.8%
Fair Value
$133.14
Current Price
$697.05
$563.91 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
Keeps 31 of every $100 in revenue as profit
Revenue surging 73.0% year-over-year
Every $100 of equity generates 20 in profit
Growing faster than its price suggests
Strong operational efficiency at 27.4%
Areas to Watch
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
ROE of 0.0% — below average capital efficiency
Premium valuation, high expectations priced in
Weak financial health signals
Earnings declined 31.9%
Comparative Analysis Report
WallStSmart ResearchBull Case : ACTU
ACTU has a balanced fundamental profile.
Bull Case : ARGX
The strongest argument for ARGX centers on Profit Margin, Revenue Growth, Return on Equity. Profitability is solid with margins at 30.5% and operating margin at 27.4%. Revenue growth of 73.0% demonstrates continued momentum.
Bear Case : ACTU
The primary concerns for ACTU are Revenue Growth, EPS Growth, Market Cap.
Bear Case : ARGX
The primary concerns for ARGX are P/E Ratio, Piotroski F-Score, EPS Growth.
Key Dynamics to Monitor
ACTU profiles as a value stock while ARGX is a growth play — different risk/reward profiles.
ARGX is growing revenue faster at 73.0% — sustainability is the question.
ARGX generates stronger free cash flow (407M), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
ARGX scores higher overall (63/100 vs 22/100), backed by strong 30.5% margins and 73.0% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Actuate Therapeutics, Inc. Common stock
HEALTHCARE · BIOTECHNOLOGY · USA
Actuate Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for patients facing serious diseases, with a particular focus on oncology. The company is advancing its proprietary drug candidates through rigorous clinical trials aimed at addressing significant unmet medical needs and enhancing patient outcomes. By concentrating on novel therapeutic mechanisms, Actuate is building a robust pipeline with the potential for strategic growth and investor value creation, positioning itself as a key player in the biotechnology landscape as it strives to make a meaningful impact.
argenx NV ADR
HEALTHCARE · BIOTECHNOLOGY · USA
argenx SE, a clinical-phase biotechnology company, focuses on the development of antibody-based therapies for the treatment of autoimmune diseases, hematology and cancer. The company is headquartered in Breda, the Netherlands.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?